Otonomy Stock

Otonomy Current Liabilities

Delisted

The Current Liabilities of Otonomy (OTIC) as of Sep 12, 2026 is 12.33 M USD. In the previous year, Current Liabilities was 10.90 M USD — a change of 13.15% (higher).

Current Liabilities

12.33 MUSD

YoY

13.15%

Last updated:

Current Liabilities of Otonomy is 2026 12.33 M USD. Current Liabilities of Otonomy was 2025 10.90 M USD. It decreases by 13.15% higher compared to the previous year.

The Otonomy Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2014
5.40 M USD
Jan 1, 2015
11.30 M USD
Jan 1, 2016
15.20 M USD
Jan 1, 2017
8.20 M USD
Jan 1, 2018
7.40 M USD
Jan 1, 2019
12.60 M USD
Jan 1, 2020
10.90 M USD
Jan 1, 2021
12.33 M USD
The Otonomy Current Liabilities history
YEARCurrent LiabilitiesYoY
12.33 MUSD+13.15%
10.90 MUSD-13.49%
12.60 MUSD+70.27%
7.40 MUSD-9.76%
8.20 MUSD-46.05%
15.20 MUSD+34.51%
11.30 MUSD+109.26%
5.40 MUSD+100.00%
2.70 MUSD+58.82%
1.70 MUSD
Access this data via the Eulerpool API

Otonomy Stock analysis

What does Otonomy do? Otonomy Inc is a biopharmaceutical company focused on developing innovative therapies for inner ear disorders. The company was founded in 2008 in San Diego, California and has since made significant advancements to bring its products to market. Otonomy's business model is based on identifying unmet medical needs in the field of otolaryngology. The company develops and markets FDA-approved ear medications that are designed in new and innovative ways to improve the treatment of hearing and balance disorders. The different divisions of Otonomy include clinical research, product development, manufacturing, and distribution. The company has an experienced team of scientists, engineers, clinical researchers, and managers who work closely together to develop and bring Otonomy's pipeline of drug candidates to market. The company has launched a number of products targeting the needs of patients with inner ear disorders. For example, the medication Otiprio was developed to treat otitis media, an inflammation of the middle ear. Otiprio is delivered directly into the ear during a minor surgery, where it quickly acts to eliminate the inflammation. Another one of Otonomy's products is Otividex, a medication developed to treat patients with Meniere's disease. This condition is a rare inner ear disorder that causes dizziness, tinnitus, and hearing loss. Otividex is also delivered directly into the ear and has shown to alleviate the dizziness symptoms and improve hearing. In recent years, Otonomy has also developed a new technology called OTO-413, which aims to improve hearing by regenerating damaged hair cells in the inner ear. The company has successfully conducted clinical trials with OTO-413 and plans to further explore and develop the technology. Otonomy has also formed partnerships with other companies and organizations in recent years to further develop its technologies and bring new products to market. For example, the company has entered into a collaboration agreement with Merck to develop new therapies for inner ear disorders. Otonomy also collaborates with a number of academic institutions and research facilities to further explore and develop the potential of its technologies. Overall, Otonomy Inc is an innovative and dynamic company dedicated to developing new therapies for inner ear disorders. With a strong pipeline of drug candidates and a dedicated group of scientists and researchers, the company is well positioned to make significant advancements in the treatment of hearing and balance disorders in the coming years. Otonomy is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Otonomy stock

Current Liabilities of Otonomy is 12.33 M USD in 2026.

Current Liabilities of Otonomy changed from 10.90 M USD to 12.33 M USD, representing a 13.15% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Otonomy since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Otonomy historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Otonomy

All Key Metrics — Otonomy